Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single‐arm, prospective phase 2 study

Type 2 diabetes in midlife and risk of cerebrovascular disease in late life: a prospective nested case−control study in a nationwide Swedish twin cohort

(2019) Rongrong Yang et al.   DIABETOLOGIA

Nasopharyngeal carcinoma

(2019) Yu-Pei Chen et al.   LANCET

Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study

(2018) Edwin P. Hui et al.   CLINICAL CANCER RESEARCH

Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials

(2018) Yu-Pei Chen et al.   CLINICAL CANCER RESEARCH

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018

(2018) A. Dimitrios Colevas et al.   Journal of the National Comprehensive Cancer Network

Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study

(2018) Xin-Ran Tang et al.   LANCET ONCOLOGY

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial

(2018) M Staehler et al.   ANNALS OF ONCOLOGY

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial

(2018) M Gross-Goupil et al.   ANNALS OF ONCOLOGY

Sorafenib for Advanced and Refractory Desmoid Tumors

(2018) Mrinal M. Gounder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment

(2017) Xiong Zou et al.   EUROPEAN JOURNAL OF CANCER

Blood Pressure Trajectories and the Risk of Intracerebral Hemorrhage and Cerebral InfarctionNovelty and Significance

(2017) Weijuan Li et al.   HYPERTENSION

Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma

(2017) Qiu-Xia Peng et al.   Oncotarget

Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy

(2016) Jian Ji Pan et al.   CANCER

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

(2016) Li Zhang et al.   LANCET

Nasopharyngeal carcinoma

(2016) Melvin L K Chua et al.   LANCET

Ten years of anti-vascular endothelial growth factor therapy

(2016) Napoleone Ferrara et al.   NATURE REVIEWS DRUG DISCOVERY

Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective

(2015) Anne W.M. Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Hyperlipidemia Attenuates Vascular Endothelial Growth Factor–Induced Angiogenesis, Impairs Cerebral Blood Flow, and Disturbs Stroke Recovery via Decreased Pericyte Coverage of Brain Endothelial Cells

(2013) Anil Zechariah et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial

(2013) Jin Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma†

(2012) C. Xue et al.   ANNALS OF ONCOLOGY

Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma

(2012) Ying Jin et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation

(2011) E. P. Hui et al.   ANNALS OF ONCOLOGY

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo

(2011) Shu Tian et al.   CANCER SCIENCE

A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma

(2011) Wan-Teck Lim et al.   CLINICAL CANCER RESEARCH

A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer

(2009) George Fountzilas et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase II study of sunitinib malate in head and neck squamous cell carcinoma

(2009) Nicholas W. Choong et al.   INVESTIGATIONAL NEW DRUGS

Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01

(2009) Jean-Pascal H. Machiels et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

(2009) Youjin Je et al.   LANCET ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Bowel Perforation After Radiotherapy in a Patient Receiving Sorafenib

(2008) Natascha A.J.B. Peters et al.   JOURNAL OF CLINICAL ONCOLOGY